MARKET

MBIO

MBIO

Mustang Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.790
-0.020
-0.52%
After Hours: 3.780 -0.01 -0.26% 19:58 06/11 EDT
OPEN
4.000
PREV CLOSE
3.810
HIGH
4.060
LOW
3.690
VOLUME
4.49M
TURNOVER
--
52 WEEK HIGH
5.22
52 WEEK LOW
2.420
MARKET CAP
330.92M
P/E (TTM)
-3.6147
1D
5D
1M
3M
1Y
5Y
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 1d ago
Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Mustang Bio (MBIO) announces updated interim data from Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas
Seekingalpha · 2d ago
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)
Benzinga · 2d ago
Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
Benzinga · 2d ago
BRIEF-Mustang Bio Announces Updated Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T in Patients with Chronic Lymphocytic Leukemia
reuters.com · 2d ago
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process...
GlobeNewswire · 2d ago
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 6d ago
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...
GlobeNewswire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBIO. Analyze the recent business situations of Mustang Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MBIO stock price target is 10.40 with a high estimate of 13.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 28.49M
% Owned: 32.63%
Shares Outstanding: 87.31M
TypeInstitutionsShares
Increased
36
6.17M
New
15
1.31M
Decreased
23
1.24M
Sold Out
12
1.89M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Executive Director/Director
Michael Weiss
President/Chief Executive Officer/Director
Manuel Litchman
Senior Vice President - Finance/Controller
Brian Achenbach
Director
Lindsay Rosenwald
Independent Director
Adam Chill
Independent Director
Neil Herskowitz
Independent Director
Michael Zelefsky
No Data
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).

Webull offers kinds of Mustang Bio Inc stock information, including NASDAQ:MBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBIO stock methods without spending real money on the virtual paper trading platform.